Drug Shortage Report for BEYFORTUS

Last updated on 2025-04-08 History
Report ID 245452
Drug Identification Number 02537214
Brand name BEYFORTUS
Common or Proper name Beyfortus
Company Name SANOFI PASTEUR LIMITED
Market Status MARKETED
Active Ingredient(s) NIRSEVIMAB
Strength(s) 100MG
Dosage form(s) SOLUTION
Route of administration INTRAMUSCULAR
Packaging sizes (GTIN)

Click here to see a list of all reports for this drug.

(See additional packaging sizes)
Additional packaging sizes 100 mg single-use, pre-filled syringe
ATC code J06BD
ATC description
Reason for shortage Demand increase for the drug.
Anticipated start date 2024-12-20
Actual start date 2024-12-19
Estimated end date 2025-03-30
Actual end date 2025-04-07
Shortage status Resolved
Updated date 2025-04-08
Company comments Sanofi is proactively securing additional doses from our global supply to quickly respond to an increase in demand, following inquiries for more doses to address a predicted surge in provincial uptake as the RSV season is projected to peak in January. The additional volumes are pre-emptive in nature and beyond the provincial contractual commitments.
Health Canada comments
Tier 3 Status No
Contact Address 1755 STEELES AVENUE WEST
TORONTO, ONTARIO
CANADA M2R 3T4
Company contact information Customer Service/Service à la clientèle: 1-800-268-4171 Vaccine Information Service/Service d'information sur les vaccins: 416-667-2611 or 1-888-621-1146

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v9 2025-04-08 English Compare
v8 2025-04-07 French Compare
v7 2025-04-07 English Compare
v6 2025-01-10 French Compare
v5 2025-01-10 English Compare
v4 2024-12-21 English Compare
v3 2024-12-11 French Compare
v2 2024-12-11 English Compare
v1 2024-12-11 English Compare

Showing 1 to 9 of 9